Papers by Jacques Epelbaum
Psychoneuroendocrinology, 1986
In addition to its classical growth hormone (GH) inhibiting action, somatostatin (SRIF) inhibits ... more In addition to its classical growth hormone (GH) inhibiting action, somatostatin (SRIF) inhibits prolactin (PRL) secretion in man and rat under specific endocrine conditions. Furthermore, SRlF counteracts the thyrotropin releasing hormone (TRH) and vasoactive intestinal peptide (VIP) stimulated prolactin release from rat adenohypophysis in vitro. Two criteria are needed to demonstrate a physiological role of SRIF in PRL control : specific receptors must be present on prolactin secreting cells, and antagonization of endogenous SRIF must affect PRL secretion in vitro. In fact ['2q]N-Tyr-SRIF binds to membranes not only of human GH-secreting adenomas, but also of prolactinomas. Specific binding characteristics are comparable in both cell types, but the density of sites in PRL-secreting adenomas is only one-quarter that in GH-secreting adenomas. In contrast, non-PRL-secreting chromophobe adenomas are devoid of specific binding. On the other hand, administration of SRIF antisera (SRIF-AS) affects both GH and PRL secretion in starved rats (a model in which pulsatile GH secretion is abolished); a marked increase in PRL plasma levels occurs, but the needed SRIF-AS concentration is higher than that for GH disinhibition. This demonstrates that endogenous SRIF may exert a negative control over PRL secretion, although lactotroph cells appear less sensitive to SRIF than somatotrophs. Since the apparent affinity of SRIF binding sites is similar on both GH and PRL secreting cells, at least in human tumor tissues, a lower density of SRIF receptors on PRL cells could account for this reduced responsiveness. Alternatively, different coupling mechanisms may be involved in the two cell types.
Frontiers in endocrinology, 2012
Somatostatin is highly expressed in mammalian brain and is involved in many brain functions such ... more Somatostatin is highly expressed in mammalian brain and is involved in many brain functions such as motor activity, sleep, sensory, and cognitive processes. Five somatostatin receptors have been described: sst(1), sst(2) (A and B), sst(3), sst(4), and sst(5), all belonging to the G-protein-coupled receptor family. During the recent years, numerous studies contributed to clarify the role of somatostatin systems, especially long-range somatostatinergic interneurons, in several functions they have been previously involved in. New advances have also been made on the alterations of somatostatinergic systems in several brain diseases and on the potential therapeutic target they represent in these pathologies.
The Journal of Physiology, 2003
Modulation of glutamatergic transmission by neuropeptides is an essential aspect of neuronal netw... more Modulation of glutamatergic transmission by neuropeptides is an essential aspect of neuronal network activity. Activation of the hypothalamic somatostatin sst2 receptor subtype by octreotide decreases AMPA glutamate responses, indicating a central link between a neurohormonal and neuromodulatory peptide and the main hypothalamic fast excitatory neurotransmitter. In mediobasal hypothalamic slices, sst2 activation inhibits the AMPA component of glutamatergic synaptic responses but is ineffective when AMPA currents are pharmacologically isolated. In mediobasal hypothalamic cultures, the decrease of AMPA currents induced by octreotide requires a concomitant activation of sst2 receptors with either NMDA and/or metabotropic glutamate receptors. This modulation depends on changes in intracellular calcium concentration induced by calcium flux through NMDA receptors or calcium release from intracellular stores following metabotropic glutamate receptor activation. These results highlight an u...
European Journal of Endocrinology, 1997
The sheep is a valuable model in which to study GH neuroregulation as its pattern of GH secretion... more The sheep is a valuable model in which to study GH neuroregulation as its pattern of GH secretion is very close to that in humans. Furthermore, important differences in somatostatin (SRIH) action between rats and sheep have been found previously. Our goal was to compare in male rat and ram pituitaries the binding characteristics of somatostatin receptors and the effect of SRIH and 17 analogues on GH release. Using radioautography, SRIH binding was seen to be evenly distributed over the anterior pituitary of both species. In the binding assay, binding sites were three times more concentrated in rats than in sheep. Important interspecies differences in the action of SRIH and its analogues were found: they inhibited GH at lower concentrations in rats than in sheep. Seven peptides displayed greater inhibitory ability in sheep than in rats while three were more potent in rats. Agonistic potencies to inhibit GH release in rats were correlated with somatostatin receptors subtype 2 (sst2) a...
Endocrinology, 2012
Fasting results in the mobilization of adipose stores and the elevation of levels of free fatty a... more Fasting results in the mobilization of adipose stores and the elevation of levels of free fatty acids (FFA). In humans, this process is driven by a release in GH. Little is known regarding the role of GH in modulating this process during early stages of fasting in the mouse. Confirmation of the role of GH in modulating FFA release in the fasting mouse is of particular importance given the frequent use of mouse models to study metabolic mechanisms. Here, we correlate the initial release of FFA throughout fasting in mice with pulsatile GH secretion. Observations illustrate the rapid release of FFA in response to food withdrawal. This does not correlate with a rise in GH secretion. Rather, we observed a striking loss in pulsatile secretion of GH throughout the first 6 h of fasting, suggesting that GH does not modulate the initial release of FFA in the mouse in response to fasting. This was confirmed in GH receptor knockout mice, in which we observed a robust fasting-induced rise in FFA...
American Journal of Physiology-Endocrinology and Metabolism, 2007
The secretion of growth hormone (GH) is inhibited by hypothalamic somatostatin (SRIF) in somatotr... more The secretion of growth hormone (GH) is inhibited by hypothalamic somatostatin (SRIF) in somatotropes through five subtypes of the somatostatin receptor (SSTR1–SSTR5). We aimed to characterize the subtype(s) of SSTRs involved in the Ca2+current reduction in GH3 somatotrope cells using specific SSTR subtype agonists. We used nystatin-perforated patch clamp to record voltage-gated Ca2+currents, using a holding potential of −80 mV in the presence of K+and Na+channel blockers. We first established the presence of T-, L-, N-, and P/Q-type Ca2+currents in GH3 cells using a variety of channel blockers (Ni+, nifedipine, ω-conotoxin GVIA, and ω-agatoxin IVA). SRIF (200 nM) reduced L- and N-type but not T- or P/Q-type currents in GH3 cells. A range of concentrations of each specific SSTR agonist was tested on Ca2+currents to find the maximal effective concentration. Activation of SSTR2 with 10−7and 10−8M L-797,976 decreased the voltage-gated Ca2+current and abolished any further decrease by S...
Hormone Research, 1989
Somatostatin (SRIF) actions in the brain and pituitary are mediated by specific receptors. Using ... more Somatostatin (SRIF) actions in the brain and pituitary are mediated by specific receptors. Using radioiodinated ligands it has been possible to characterize the kinetics of specific binding sites in the brain and pituitary, and to determine their cellular localization by autoradiography. At the pituitary level, the inhibition of growth hormone, prolactin and thyrotropin secretions induced by SRIF is mediated through a single binding site which is coupled to the inhibition of adenylate cyclase. In the brain, SRIF receptors are localized on neurons and glial cells and are also coupled to adenylate cyclase inhibition. Two sites are differentiated in the brain with an analogue of somatostatin, SMS 201995. In humans, SRIF-binding sites have been related to a number of pathologies. At the pituitary level, it has been shown that the number of binding sites was negatively correlated to growth hormone levels in acromegaly. Furthermore, SRIF-binding sites were undetectable in a patient which did not respond to SMS 201995 therapy. In the brain, meningiomas and gliomas are rich in SRIF binding sites. This suggests a possible role for SRIF on glia. In neurodegenerative diseases, cortical SRIF concentrations are decreased in Alzheimer's and Parkinson's disease associated with dementia while SRIF-binding sites are only affected in Alzheimer's disease. In conclusion, the physiological role of SRIF in the brain and pituitary can be evaluated by studying the receptors of the peptide. Such studies allow to question the implication of SRIF in endocrine and neuropathologies.
International Journal of Molecular Sciences, 2017
Ghrelin is an octanoylated peptide that acts via its specific receptor, the growth hormone secret... more Ghrelin is an octanoylated peptide that acts via its specific receptor, the growth hormone secretagogue receptor type 1a (GHSR-1a), and regulates a vast variety of physiological functions. It is well established that ghrelin is predominantly synthesized by a distinct population of endocrine cells located within the gastric oxyntic mucosa. In addition, some studies have reported that ghrelin could also be synthesized in some brain regions, such as the hypothalamus. However, evidences of neuronal production of ghrelin have been inconsistent and, as a consequence, it is still as a matter of debate if ghrelin can be centrally produced. Here, we provide a comprehensive review and discussion of the data supporting, or not, the notion that the mammalian central nervous system can synthetize ghrelin. We conclude that no irrefutable and reproducible evidence exists supporting the notion that ghrelin is synthetized, at physiologically relevant levels, in the central nervous system of adult mammals.
Progress in Neurobiology, 1996
Somatostatin was first identified chemically in 1973, smce when much has been established about i... more Somatostatin was first identified chemically in 1973, smce when much has been established about its synthesis, storage and release. It has important physiological actions, including a tonic inhibitory effect on growth hormone release from the pituitary. It has other central actions which are not well understood but recent cloning studies have identified at least five different types of cell membrane receptor lbr somatostatin. The identification of their genes has allowed studies on the distribution of the receptor transcripts in the central nervous system where they show distinct patterns of distribution, although there is evidence to indicate that more than one receptor type can co-exist in a single neuronal cell. Receptor selective radioligands and antibodies are being developed to further probe the exact location of the receptor proteins. This will lead to a better understanding of the ftmctional role of these receptors in the brain and the prospect of determining the role, if any, of somatostatin in CNS disorders and the identification of potentially useful medicines.
Journal of Clinical Investigation, 2006
The growth hormone (GH) secretagogue receptor (GHSR) was cloned as the target of a family of synt... more The growth hormone (GH) secretagogue receptor (GHSR) was cloned as the target of a family of synthetic molecules endowed with GH release properties. As shown recently through in vitro means, this receptor displays a constitutive activity whose clinical relevance is unknown. Although pharmacological studies have demonstrated that its endogenous ligand-ghrelin-stimulates, through the GHSR, GH secretion and appetite, the physiological importance of the GHSR-dependent pathways remains an open question that gives rise to much controversy. We report the identification of a GHSR missense mutation that segregates with short stature within 2 unrelated families. This mutation, which results in decreased cell-surface expression of the receptor, selectively impairs the constitutive activity of the GHSR, while preserving its ability to respond to ghrelin. This first description, to our knowledge, of a functionally significant GHSR mutation, which unveils the critical importance of the GHSR-associated constitutive activity, discloses an unusual pathogenic mechanism of growth failure in humans.
Handbook of Chemical Neuroanatomy, 2000
... the other hand. CH-275 is the only compound that was consistently reported as being selective... more ... the other hand. CH-275 is the only compound that was consistently reported as being selective for the sstl/sst4 subfamily. Recently a non-peptide agonist was introduced as sst4-selective (Ankersen et al., 1998). There are also ...
Brain Research, 1990
The present study examined the effects of the impairment of corticostriatal and nigrostriatal dop... more The present study examined the effects of the impairment of corticostriatal and nigrostriatal dopaminergic transmission on the mean number and the topographical distribution of somatostatin-containing neurons in frontal sections of the rat rostral striatum. These neurons, visualized by an immunohistoehemical method using a specific anti-somatostatin(28) antibody were shown to be unevenly distributed; the number of immunoreactive perikarya being consistently lower in the dorsolateral and higher in the middle areas of striatal sections than in the remaining parts of the structure. Such a distribution and number were not altered either by unilateral 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal dopaminergic neurons after 2-to 3-week survival periods, or by a-methylparatyrosine-induced dopamine depletion. In animals with similar 6-OHDA-induced lesions, no change in the striatal concentration of somatostatin measured by radioimmunoassay was observed. These results suggest that somatostatin levels in striatal neurons are not under a dopaminergic influence in contrast to that previously described for neuropeptide Y, although both peptides are thought to coexist extensively in the same striatal neuron population. On the contrary, extensive unilateral frontoparietal ablation of the cerebral cortex elicited, 2-3 weeks later, a significant increase in the mean number of somatostatin-immunoreactive cells per section in the ipsilateral striatum preferentially localized to the dorsolateral zone of the structure with no change in the contralateral side. Data from immunohistochemical studies were further discussed in comparison with results obtained by radioimmunoassay showing that similar cortical lesion induced no change in somatostatin endogenous levels in the ipsilateral striatum and a 30% decreased concentration of the peptide in the contralateral striatum. These data suggest that the corticostriatal pathway influences the expression of somatostatin at either a translational, processing or metabolic level in a topographically restricted population of striatal somatostatin-containing neurons.
des services d'édition numérique de documents scientifiques depuis 1998.
Neuroendocrinology, 1992
Distribution of growth-hormone-releasing hormone (GHRH) cell bodies and somatostatin binding site... more Distribution of growth-hormone-releasing hormone (GHRH) cell bodies and somatostatin binding sites were compared in the mediobasal hypothalamus of the rat. GHRH-synthesizing neurons were visualized by in situ hybridization, using as 35S-labelled synthetic oligonucleotide (45 mere), and 125I-Tyr0-DTrp8-somatostatin (125I-SRIH) binding sites by light-microscopic radioautography on adjacent 20-microns-thick frozen mirror sections. GHRH mRNA hybridizing cells were detected mostly in the ventrolateral portion of the arcuate nucleus (ARC) and around the perimeter of the ventromedial nucleus (VMN). Comparison with the distribution of pericellular 125I-SRIH binding sites allowed to differentiate three types of cells: (1) GHRH perikarya not associated with pericellular 125I-SRIH binding sites around the perimeter of the VMN, (2) 125I-SRIH-labelled cells, not associated with GHRH perikarya in the periventricular zone along the dorsal part of the third ventricle, and (3) in the ventrolateral portion of the ARC, GHRH mRNA-labelled neurons had the same distribution as 125I-SRIH-labelled cells. Furthermore, on adjacent sections, the number of both labelled cells were correlated (r = 0.68; p less than 0.001). In this last population, the extent of colocalization of 125I-SRIH binding sites on GHRH mRNA-labelled neurons was further investigated in adjacent 5-microns-thick sections. The proportions of cells GHRH mRNA and 125I-SRIH allowed to differentiate three subdivisions of the arcuate: the periventricular (PV), ventrobasal (VB) and lateral portions. In the PV-ARC, 27% of GHRH-synthesizing cells were coidentified as 125I-labelled while only 6% of 125I-labelled cells contained GHRH mRNA. In the VB-ARC the proportion of double-labelled cells was equivalent (31 and 26%, respectively for GHRH mRNA and 125I-SRIH).(ABSTRACT TRUNCATED AT 250 WORDS)
Journal of Neuroendocrinology, 1989
The regulation of growth hormone secretion depends upon the complex interplay between two hypotha... more The regulation of growth hormone secretion depends upon the complex interplay between two hypothalamic hypophysiotropic factors: growth hormone-releasing factor and somatotropin release inhibiting factor or somatostatin. Interactions between these two neurohormones appear to be exerted both distally, at the level of pituitary somatotropes, and proximally, within the hypothalamus. In an attempt to detect a possible anatomical substrate for central interactions between the two neurohormones, we compared the autoradiographic distribution of specifically labeled somatostatin binding sites with the immunohistochemical distribution of growth hormone-releasing factor-containing neurons in the hypothalamus of adult rats. Somatostatin binding sites were labeled in vitro by incubating serial brain sections with [1251]TyrO-DTrp8-somatostatin. Growth hormone-releasing factor-immunoreactive neurons were visualized in a second set of animals, using an antiserum raised against synthetic rat growth hormone-releasing factor (1-29) NH,. In light microscopic autoradiograms of sections incubated with [ '251]somatostatin the label was found to be concentrated over small, round or oval neuronal perikarya clustered within the ventrolateral aspect of the arcuate nucleus. The topographic distribution of these [ '251]somatostatin-labeled cells was similar to that of growth hormone-releasing factor-immunoreactive neurons detected within the same region. Moreover, the number of [1251]somatostatin-labeled cells was found to vary in parallel with that of growth hormone-releasing factor-immunoreactive neurons throughout the rostro-caudal extent of the arcuate nucleus (coefficient of correlation r = 0.80). These results suggest that somatostatin binding sites may be directly associated with the perikarya of arcuate growth hormone-releasing factor neurons. Such an association would provide an anatomical substrate for a direct regulation of growth hormone-releasing factor secretion by somatostatin at the hypothalamic level. A -2 8 GRF-& iMMUNOREACTlVlTY . pic;. 3. Atlas of the rat hypothalamus comparing the distribution of [1251]SRIF-labeled cells (left panel) with that of GRF-I -imunoreactive neurons (right Panel). Schematics and nomenclature according to . Both types of labeled cells are represented with black dots. Semiquantitative estimates based on camera lucida drawings from three different cases. AHy-anterior hypothalamus; Arc-arcuate nucleus; DM-dorsomedial hypothalamic nucleus; ME-median eminence; VM-ventromedial hypothalamic nucleus; I11 V-third ventricle; Pa-paraventricular hypothalamic nucleus; PE-periventricular hypothalamic nucleus; PMV-ventral premammillary nucleus; f-fornix; ic-internal capsule; opt-optic tract; sox-supraoptic decussation.
Uploads
Papers by Jacques Epelbaum